Related Experiment Video
Updated: Jun 23, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Importance of PTM of FLT3 in acute myeloid leukemia
Abstract:
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase expressed in hematopoietic cells. Internal-tandem duplication domain (ITD) mutation and tyrosine kinase domain (TKD) mutation are the two most common mutations in acute myeloid leukemia (AML). Post-translational modifications (PTMs) of FLT3, such as glycosylation and ubiquitination, have been shown to impact various aspects of the protein in both wild-type (WT) and mutant forms of FLT3. In this review, we describe how the glycosylation status of FLT3 affects its subcellular localization, which significantly impacts the activation of downstream signaling, and the impact of specific ubiquitination on FLT3 function and stability, which may be associated with disease progression. Moreover, potential novel therapeutic strategies involving a combination of FLT3 tyrosine kinase inhibitors and drugs targeting glycosylation or ubiquitination are discussed.
Insights
Post-translational modifications like glycosylation and ubiquitination impact FMS-like tyrosine kinase 3 (FLT3) function in acute myeloid leukemia. Targeting these modifications alongside FLT3 inhibitors may offer novel therapeutic strategies.
Area of Science:
- Molecular Biology
- Hematology
- Cancer Research
Background:
- FMS-like tyrosine kinase 3 (FLT3) is a key receptor tyrosine kinase in hematopoietic cells.
- Internal-tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations in FLT3 are prevalent in acute myeloid leukemia (AML).
- Post-translational modifications (PTMs) significantly influence FLT3 protein behavior in both wild-type (WT) and mutated forms.
Purpose of the Study:
- To review the impact of FLT3 glycosylation on subcellular localization and downstream signaling.
- To examine the role of FLT3 ubiquitination in protein function, stability, and potential association with AML progression.
- To discuss novel therapeutic strategies combining FLT3 inhibitors with agents targeting glycosylation or ubiquitination.
Main Methods:
- Literature review synthesizing current research on FLT3 post-translational modifications.
- Analysis of studies detailing the effects of glycosylation on FLT3 localization and signaling pathways.
- Examination of research on ubiquitination's influence on FLT3 stability and its clinical relevance in AML.
Main Results:
- Glycosylation status of FLT3 critically affects its subcellular distribution, impacting downstream signaling activation.
- Specific ubiquitination patterns of FLT3 influence its function and stability, potentially correlating with AML disease progression.
- Emerging evidence suggests PTMs are crucial modulators of FLT3 activity in AML.
Conclusions:
- Understanding FLT3 PTMs, including glycosylation and ubiquitination, is vital for comprehending AML pathogenesis.
- Targeting FLT3 PTMs presents a promising avenue for developing innovative therapeutic approaches.
- Combination therapies involving FLT3 inhibitors and modulators of glycosylation or ubiquitination warrant further investigation for AML treatment.
Related Concept Videos
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
01:15Differentiation of Common Myeloid Progenitor Cells